8:00 am
REGISTRATION AND MORNING COFFEE

8:50 am Chairs Opening Remarks

  • Tarek Samad Senior Vice President & Head of Research, Lundbeck

REVOLUTIONIZING NEUROINFLAMMATORY BIOMARKER DEVELOPMENT TO ACCELERATE SYMPTOM RECOGNITION, DIAGNOSIS & PROGRESSION

9:00 am Reviewing the Current Status of Biomarker Discovery & Development to Direct Future Neuroimmunology Advancements

  • Tarek Samad Senior Vice President & Head of Research, Lundbeck

Synopsis

  • Outlining where we have seen evidence of progress and where the field must improve
  • Uncovering significant learnings from past failings and optimistic implications for the future
  • Translating learnings from the field of immunology to unlock novel discoveries of neuroinflammatory biomarkers

9:30 am Evaluating the Role of Biomarkers for Evaluating Treatment Response & Disease Progression in Neuroinflammatory Disorders

  • Sherman Jia Group Medical Director, Biomarker Development, Genentech Inc

Synopsis

  • Dissecting biomarkers of acute inflammatory versus chronic insidious injury in Multiple Sclerosis
  • Evaluating the direct and indirect impacts of a high-efficacy disease modifying treatment
  • Identifying proof-of-activity biomarkers correlating with clinical outcomes and their implications for drug development

10:00 am
MORNING COFFEE BREAK

11:00 am Investigating Blood-Derived Indications of the Inflammatory Cascade in Pediatric Traumatic Brain Injury

  • Jennifer Munoz Pareja Associate Professor, Division of Pediatric Critical Care Medicine, University of Miami, Miller School of Medicine

Synopsis

  • Advancing neuronal injury biomarkers to detect neuroinflammation
  • Diagnostic utility of the inflammasome in pediatric TBI and potential therapeutic targets
  • Prognostic capabilities of the inflammasome activation in pediatric TBI

11:30 am Roundtable Discussion: Comparing Neuroinflammatory Biomarker Development Across Different Neurological Diseases

  • Kevin Dines Scientific Senior Director, Preclinical Sciences, Bristol Myers Squibb
  • Bastian Zinnhardt Biomarker Experimental Medicine Leader, Roche

Synopsis

One of the biggest challenges in developing neuroimmunology drugs is distinguishing between the underlying CNS pathologies and inflammatory subtypes that vary across different neurological conditions. For this session, attendees will be organized into several roundtables, each discussing how biomarkers are currently being developed to detect neuroinflammation in one of the following neurological indications: Alzheimer’s, Parkinson’s, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

12:15 pm
NETWORKING LUNCH

SUBVERTING THE BLOOD-BRAIN BARRIER AS AN OBSTACLE TO NEUROIMMUNOLOGY DRUG DEVELOPMENT

1:15 pm Evaluating the Role of Biomarkers for Evaluating Treatment Response & Disease Progression in Neuroinflammatory Disorders

Synopsis

  • Leveraging Organ-on-Chip technology for studying neuroinflammatory diseases
  • Understanding how neuroimmune interactions disrupt the blood-brain barrier in several neurological disorders
  • Deciphering how to restore the blood-brain barrier breakdown, evident in many neuroinflammatory conditions

1:45 pm Exploring the Crosstalk Between Peripheral & Central Inflammatory Cells to Enhance Understanding of Inflammatory Mediation in Neurological Disease

  • Dimitry Ofengeim Head of Precision Neurology & Neuroinflammation Cluster, Sanofi

Synopsis

  • Deciphering overlap in the mechanistic basis of inflammation in the periphery and in the CNS
  • Understanding the role of the blood-brain barrier in facilitating this communication
  • Assessing the role of infiltrating peripheral immune cells in neurodegenerative diseases

2:15 pm
AFTERNOON BREAK

DECONSTRUCTING IN VIVO MODELS TO SIMULATE HUMAN NEUROIMMUNE ACTIVATION & CNS INFLAMMATION

2:45 pm Panel Discussion: Leveraging In Vivo Neuroimmune Modelling to Streamline Translation into the Clinic

  • Kevin Dines Scientific Senior Director, Preclinical Sciences, Bristol Myers Squibb
  • Manuela Polydoro Head of Translational Medicine, Muna Therapeutics

Synopsis

  • Assessing the value of current in vivo models to help understand neuroinflammatory disease progression
  • Discussing how to select activating agents specific to the inflammatory pathway of interest
  • Harnessing in vivo models to confirm whether a drug is having therapeutic effects within the CNS

3:30 pm Exploring Rodent Models of Neurological Disease to Improve Understanding of Neuroimmunological Pathophysiology

Synopsis

  • Navigating the differences in mice vs human neuroimmune physiology and the neuroinflammatory cells that comprise the CNS
  • Overcoming the lack of conservation between rodent and human modelling
  • Comparing the immune response in the brain to pathology in mice and humans

4:00 pm Overcoming the Technical Limitations of In Vivo Models for Constituting Human Neuroinflammatory Progression

  • Florian Wanke Discovery Scientist Neuroimmunology and Neuroinflammation, Roche

Synopsis

  • Critically analyzing the workflow of in vivo preclinical models and exploring additional models to put in place
  • Evaluating the translatability of in vivo models for neuroinflammatory targeting
  • Holistically assessing known effectors and targets that have yet to be deemed relevant in the neuroimmunology setting

4:30 pm Chair’s Closing Remarks & End of Conference